First hormone replacement therapy for parathyroid disorder
Orphan medicine Natpar recommended by CHMP for conditional marketing authorisation
The European Medicines Agency (EMA) has recommended granting a conditional marketing authorisation in the European Union (EU) for Natpar (parathyroid hormone). Natpar is proposed as a treatment for patients with chronic hypoparathyroidism who cannot be adequately controlled with standard treatment with calcium and vitamin D. It is the first approved replacement therapy with parathyroid hormone for this rare condition.
#EMA #EuropeanMedicinesAgency #Parathyroiddisorder #chronichypoparathyroidism #approvedreplacementtherapy #parathyroidhormone #PharmaNews
